AbbVie, Inc (NYSE:ABBV) reported earnings last week, with revenue up 5% year-over-year to $4.6 billion. Adjusted eps grew to $0.71, up 4% from last year and above management's previous guidance range.
Humira, the current best-selling drug in the world, generated $2.6 billion in sales this past quarter, up 18% in constant currencies. SG&A expenses grew to 29% of sales, driven in part by preparation for the potential launch of its interferon-free all-oral hepatitis C cocktail, which was recently submitted to the FDA for approval. Like Gilead (NASDAQ:GILD), AbbVie's management didn't include potential hepatitis C sales in revenue guidance for the rest of the year.
The hepatitis C fight is heating up, and in this video, Motley Fool health care analysts David Williamson and Michael Douglass discuss what AbbVie investors should be focusing on for the rest of the year.
6 stock picks poised for incredible growth -- can they beat AbbVie and Gilead?
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.
David Williamson owns shares of AbbVie. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.